| http://www.w3.org/ns/prov#value | - The merger, which is expected to close in the 2009 fourth quarter, is subject to the satisfaction of customary closing conditions and regulatory approvals, including expiration or termination of the applicable waiting period und...Novavax Reports Second Quarter 2009 Financial Results...ter included the following: Completed subject enrollment in the second Phase II study of its tri...cautions that
|
